Full-Time

Associate Director Operational Technology Automation

Posted on 4/12/2025

AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

No salary listed

Senior

Shepherdsville, KY, USA

In-person working is required for a minimum of three days per week.

Category
IT Project Management
System Administration
IT & Security
Required Skills
Operating Systems
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree in science, engineering, or related field
  • 5+ years validation experience in pharmaceutical/biological/manufacturing/ or distribution environment
  • General knowledge of regulatory requirements, including but not limited to FDA, DEA, DOT, EPA, etc.
  • Demonstrated knowledge of computer hardware, software, and operating systems with focus on network support and local area networks
  • Proven experience in design, configuration and/or testing of systems
  • Knowledge of computerized system validation and strong technical writing abilities
  • Proficiency in basic digital literacy required including hands-on working knowledge of MS Word, Excel
  • Possess strong analytical skills and overall business acumen knowledge
  • Demonstrated strong interpersonal, communication, organizational negotiation, and strategic planning and problem-solving skills
Responsibilities
  • Primary IT liaison between LVDC Operations, Quality, and Facility Departments.
  • Serve as site IT administrator for all locally owned site computerized automation systems by maintaining domain access control, regular administration of locally owned virtual computers, point of contact for offline servers, and perform special requests by Operation, Quality and Facility Departments.
  • Owner of the site Computerized System Validation Master Plan.
  • Lead validation projects and periodic reviews as the need arises.
  • Maintain local Process Control Network uptime/performance and ensure security of locally produced data.
  • Responsible for maintenance of site computerized system registry and configuration management database.
  • Responsible for communication and identification of risks in the IT system risk registry.
  • Responsible for site computerized system validation and technical investigation support.
  • Write validation documents related to computerized system validation.
  • Write and maintain Validation/Computerized system site specific procedures.
  • Support implementation of validated computerized system change requests and resolution of process deviations through technical knowledge, and use of root cause investigation tools, execution of supporting validation studies, and documentation review and approval.
  • Work with system validation and system contractors as required.
  • Liaise with Regional, Global OPS IT and plan site IT demand accordingly.
  • Perform and direct the validation activities including start up protocols, technical reports, specifications, and risk assessments.
  • Communicate effectively to management across departments, validation goals, computerized system risks, priorities and policy.
  • Ensures site validation SOPs and Master Plans are aligned with Corporate IT policies and standards.
Desired Qualifications
  • Project management
  • Supplier management experience
  • Extensive knowledge of supply chain principles: GMP, GDP, Regulatory
  • Familiar with Lean leadership principles and methods

AstraZeneca focuses on discovering, developing, and selling prescription medicines, primarily in three areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Their products are developed through extensive research and development, which includes rigorous clinical trials and regulatory approvals before reaching the market. AstraZeneca differentiates itself from competitors by investing heavily in scientific research and fostering collaborations through initiatives like their Open Innovation program, which shares resources with the scientific community to speed up drug discovery. The company's goal is to advance healthcare by creating effective treatments for serious diseases and expanding their product offerings through strategic partnerships.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven drug discovery could enhance AstraZeneca's R&D efficiency.
  • Real-world evidence supports AstraZeneca's efforts in demonstrating drug efficacy and safety.
  • Personalized medicine aligns with AstraZeneca's focus on precision medicine.

What critics are saying

  • AstraZeneca faces a class-action lawsuit over alleged Soliris monopoly practices.
  • AI tools for breast cancer screening may face challenges due to minority underrepresentation.
  • Investment in Dunkirk may be at risk due to potential regulatory changes.

What makes AstraZeneca unique

  • AstraZeneca focuses on three main therapy areas: Oncology, Cardiovascular, and Respiratory.
  • The company invests heavily in R&D to create innovative prescription medicines.
  • AstraZeneca's A.Catalyst Network fosters global collaboration and innovation in healthcare.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

Cision
Apr 22nd, 2025
Enhertu Combination Improved Pfs In 1L Her2+ Mbc

Enhertu combination improved PFS in 1L HER2+ mBC

Life Sciences IP Review
Apr 17th, 2025
AstraZeneca unit faces class-action suit over alleged Soliris monopoly

AstraZeneca unit faces class-action suit over alleged soliris monopoly.

Our Health Needs
Apr 11th, 2025
Study: Racial, ethnic minorities are underrepresented in AI mammogram interpretation

In 2024, AI biotech company Owkin partnered with pharma giant AstraZeneca to develop an AI-powered tool designed to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides.

Medical Update Online
Apr 11th, 2025
AstraZeneca showcases progress in immunisation and real-world evidence addressing global infectious disease burden at ESCMID Global 2025

AstraZeneca showcases progress in immunisation and real-world evidence addressing global infectious disease burden at ESCMID Global 2025.

Cision
Apr 11th, 2025
Result Of Agm

11 April 2025Results of Annual General Meeting held on 11 April 2025AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 9 - 12 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.Resolution. Votes for. % of votes cast

INACTIVE